1T. Kantola,J. T. Backman,M. Niemi,K. T. Kivist?,P. J. Neuvonen. Effect of fluconazole on plasma fluvastatin and pravastatin concentrations[J] 2000,European Journal of Clinical Pharmacology(3):225～229
2T. Kantola,K. T. Kivist?,P. J. Neuvonen. Effect of itraconazole on cerivastatin pharmacokinetics[J] 1999,European Journal of Clinical Pharmacology(11):851～855
3W. Mück,K. Ochmann,G. Rohde,S. Unger,J. Kuhlmann. Influence of erythromycin pre- and co-treatment on single-dose pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin[J] 1998,European Journal of Clinical Pharmacology(6):469～473
2Weinshilboum R. Inheritance and drug response[J]. N Engl J Med, 2003,348(6) :529.
3Phillips KA, Veenstra DL, Oren E, et al. Potential role of pharmacogenomics in reducing adverse drug reactions [J].JAMA,2001,286(18) :2270.
4Cadieux RJ. Antidepressant drug interactions in the elderly.Understanding the P-450 system is half the battle in reducing risks[J]. PostgradMedJ, 1999,106(6):231,237,245.
5Cupp MJ, Tracy TS. Cytochrome P450: new nomenclature and clinical implications[J]. Am Fam Physician, 1998, 57(1):107.
6Grant DM,Goodfellow GH,Sugamori KS, etal. Pharmacogenetics of the human arylamine N-acetyltransferases [J].Pharmacology, 2000,61 (3): 204.
7Jerling M, Dahl ML, Aberg-Wistedt A, et al. The CYP2D6 genotype predicts the oral clearance of the neuroleptic agents perphenazine and zuclopenthixol[J]. Clin Pharmacol Ther,1996,59(4) :423.
8Cai WM,Chen B,Cai MH,et al. The influence of CYP2D6 activity on the kinetics of propafenone enantiomers in Chinese subjects[J]. Br J Clin Pharmacol, 1999,47(5) :553.
9Hutzler JM, Tracy TS. Atypical kinetic profiles in drug metabolism reactions[J]. Drug Metab Dispos, 2002,30 (4):355.
10Papp-Jambor C, Jaschinski U, Forst H. Cytochrome P450 enzymes and their role in drug interactions[J]. Anaesthetist,2002, 51(1): 2.
